| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSMD7 |
| Uniprot No | P51665 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-324aa |
| 氨基酸序列 | MPELAVQKVV VHPLVLLSVV DHFNRIGKVG NQKRVVGVLL GSWQKKVLDV SNSFAVPFDE DDKDDSVWFL DHDYLENMYG MFKKVNARER IVGWYHTGPK LHKNDIAINE LMKRYCPNSV LVIIDVKPKD LGLPTEAYIS VEEVHDDGTP TSKTFEHVTS EIGAEEAEEV GVEHLLRDIK DTTVGTLSQR ITNQVHGLKG LNSKLLDIRS YLEKVATGKL PINHQIIYQL QDVFNLLPDV SLQEFVKAFY LKTNDQMVVV YLASLIRSVV ALHNLINNKI ANRDAEKKEG QEKEESKKDR KEDKEKDKDK EKSDVKKEEK KEKK |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PSMD7重组蛋白的3篇参考文献的简要总结(文献为虚构示例，供参考)：
---
1. **文献名称**: "Recombinant PSMD7 facilitates 26S proteasome assembly in vitro"
**作者**: Bard, J.M. et al.
**摘要**: 本研究通过在大肠杆菌中表达并纯化重组PSMD7蛋白，证明其在体外能够促进26S蛋白酶体19S调节颗粒的组装。实验显示PSMD7与其他亚基(如PSMC3)相互作用，并通过ATP酶活性调控蛋白酶体功能。
2. **文献名称**: "Structural insights into PSMD7 function via X-ray crystallography"
**作者**: Smith, R.K. et al.
**摘要**: 利用重组PSMD7蛋白的晶体结构解析，揭示了其C端螺旋结构域在结合泛素化底物中的关键作用，为理解蛋白酶体识别降解信号的分子机制提供了结构基础。
3. **文献名称**: "PSMD7 overexpression promotes tumor proliferation through proteasome dysregulation"
**作者**: Zhang, L. et al.
**摘要**: 通过哺乳动物细胞表达重组PSMD7.研究发现其过表达导致蛋白酶体活性异常，并加速癌细胞的周期进程，提示PSMD7可能作为癌症治疗的潜在靶点。
---
注：以上文献为示例，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献。
**Background of PSMD7 Recombinant Protein**
PSMD7 (Proteasome 26S Subunit, Non-ATPase 7) is a critical component of the 26S proteasome, a large multi-subunit complex responsible for the degradation of ubiquitinated proteins in eukaryotic cells. As part of the 19S regulatory particle (RP) of the proteasome, PSMD7 plays a role in recognizing polyubiquitinated substrates, deubiquitination, and facilitating the unfolding and translocation of target proteins into the 20S core particle for proteolytic cleavage. This process is essential for maintaining cellular protein homeostasis, regulating key processes like cell cycle progression, stress responses, and signal transduction.
The PSMD7 recombinant protein is engineered using molecular cloning techniques, typically expressed in *E. coli* or mammalian cell systems, followed by purification to achieve high homogeneity. Its recombinant form retains structural and functional integrity, enabling studies on proteasome assembly, substrate recognition, and interactions with other proteasomal subunits or regulatory molecules. Researchers utilize PSMD7 recombinant protein to investigate dysregulation of the ubiquitin-proteasome system (UPS), which is implicated in pathologies such as cancer, neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s diseases), and autoimmune conditions.
Additionally, PSMD7 is explored as a potential therapeutic target. Inhibitors or modulators of the 19S RP, including PSMD7. could offer alternatives to current proteasome-targeting drugs (e.g., bortezomib), which primarily target the 20S core and often exhibit off-target effects. Structural and functional insights gained from PSMD7 recombinant protein studies contribute to drug discovery efforts aimed at refining UPS modulation with greater specificity.
Overall, PSMD7 recombinant protein serves as a vital tool for advancing understanding of proteasome biology and developing novel therapeutic strategies for UPS-related diseases.
×
